Levothyroxine Sodium Tablets 25 mcg
Major Pharmaceuticals recalls Levothyroxine 25 mcg tablets due to subpotency.
Stop using the recalled tablets and contact your healthcare provider for guidance. Return the product to the place of purchase for a refund or exchange.
Why it was recalled
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, USP, 25 mcg, 100-count cartons, due to subpotency. Subpotent drug may lead to inadequate thyroid hormone replacement, potentially causing hypothyroidism symptoms.
Is mine affected?
This recall covers 12 products. Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
Levothyroxine Sodium Tablets, USP
| Lot code | Strength | NDC / UPC | Recall # |
|---|---|---|---|
| N02172A, N02172B, 2026, N02172 | 75 mcg | – | D-0709-2026 |
| N02167A, 2026, N02167 | 150 mcg | – | D-0711-2026 |
| N02310, 2027 | 88 mcg | NDC 0904-6952-61 | D-0703-2026 |
| N02172, 2026 | 75 mcg | NDC 0904-6951-61 | D-0702-2026 |
| N02266A, N02266B, 2026, N02266 | 125 mcg | – | D-0710-2026 |
| N02212, 2026 | 25 mcg | NDC 0904-6949-61 | D-0700-2026 |
| N02200, 2026 | 50 mcg | NDC 0904-6950-61 | D-0701-2026 |
| N02266, 2026 | 125 mcg | NDC 0904-6955-61 | D-0705-2026 |
Show all 12 products
| Lot code | Strength | NDC / UPC | Recall # |
|---|---|---|---|
| N02212A, N02212B, 2026, N02212 | 25 mcg | – | D-0707-2026 |
| N02203, 2026 | 112 mcg | NDC 0904-6954-61 | D-0704-2026 |
| N02167, 2026 | 150 mcg | NDC 0904-6956-61 | D-0706-2026 |
| N02200A, N02200B, 2026, N02200 | 50 mcg | – | D-0708-2026 |
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Other Drug Potency recalls
Editorial summary by Recall Canary · summary updated 2026-09-03 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification